| SIX
Swiss Exchange Europe’s leading exchange for life sciences companies
With a public offering of securities in Switzerland, and thanks to the tremendous placing power afforded by the Swiss-based investment banks, life science companies gain access to a sectorally experienced, highly competent and broadly international circle of investors.
Further information on the topic of IPOs on the SIX Swiss Exchange can be accessed at: www.six-swiss-exchange.com/download/about/div_pub/swx_ipoguide_en.pdf Should you have further questions with regard to a public offering of securities, the various stock market segments or any other exchange-related topic, please feel free to contact our Issuer & Investor Relations team. SIX Swiss Exchange |
|
Sponsors
Sachs Associates has developed an extensive knowledge of key individuals operating within the European and global biotech community. This, with a growing reputation for excellence, puts Sachs Associates at the forefront of the industry and provides a powerful tool to increase the position of your company in this market.
All of our sponsorship packages are tailor-made to each client, allowing your organisation to gain the most out of sponsoring our industry driven events.
- Some benefits of Sponsorship:
- Sponsorship is an effective marketing tool which improves the image of your organisation through supporting events that your target market finds attractive.
- Sponsorship is a way for large corporations to boost profits while establishing goodwill. For smaller companies, sponsorship enhances their public profile at little cost.
- Besides enhancing visibility and image, sponsorship helps develop closer and better relationships with existing and potential customers and clients.
- Sponsorship creates positive PR and raises awareness of the organisation as a whole and often generates media coverage.
Whatever the reason or level of sponsorship, our packages are especially designed to complement and promote your organisation, so for further information or to discuss sponsorship opportunities please contact Rosa Lippard at rosa@sachsforum.com
| DyoDelta Biosciences DyoDelta Biosciences Ltd., is a London based company specialising in providing Business Development and Due Diligence support to companies and investors in the Pharma / Biotech sector. DyoDelta Biosciences' team averages more than 20 years experience per person and more than 150 years of cumulative experience. DyoDelta Biosciences has thousands of contacts at the senior corporate level worldwide and across the life sciences industry. The team's executives have put together multiple types of deals, including R&D collaborations, strategic alliances, product licensing, acquisitions, disposals, financings and local geography partnering, with NPVs adding to billions of dollars. DyoDelta Biosciences covers Europe, the US and Japan, in guiding and supporting pharma and biotech companies, investors, institutions and organisations in corporate transactions, evaluation and due diligence. Corporate deals with pharma companies are key to progressing development, providing funding, validation and also the trigger to investors for either an IPO or further funding.
For more information, please contact: Tel: +44 20 7396 5572 |
 |
| Merck Serono International SA Our active ingredient is Innovation At Merck Serono, we are actively committed to bringing therapeutic innovations to patients. We specialize in the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases and other conditions with unmet medical needs. Around the world, over 17,000 employees work to discover, develop, manufacture and commercialize Merck Serono’s prescription therapies, available in over 150 countries. In 2007, sales of Merck Serono products generated total revenues of €4.5 billion. We devote 20% of these earnings to the pursuit of innovative new therapies through our own research and development, strategic alliances and agreement. |
 |